• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Regeneron Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/1/25 6:49:57 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REGN alert in real time by email
    regn-20250801
    0000872589false00008725892025-08-012025-08-01

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 1, 2025 (August 1, 2025)

    REGENERON PHARMACEUTICALS, INC.
    (Exact name of registrant as specified in its charter)
    New York
    000-19034
    13-3444607
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (I.R.S. Employer Identification No.)
    777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
    (Address of Principal Executive Offices, including zip code)

    (914) 847-7000
    Registrant's telephone number, including area code


    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock - par value $.001 per shareREGNNASDAQ Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐








    Item 2.02    Results of Operations and Financial Condition.

    On August 1, 2025, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended June 30, 2025. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.

    The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.


    Item 9.01    Financial Statements and Exhibits.

    (d) Exhibits

    99.1 Press Release, dated August 1, 2025, Reporting Second Quarter 2025 Financial and Operating Results.

    104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.





    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Date: August 1, 2025
    REGENERON PHARMACEUTICALS, INC.
    By:/s/ Joseph J. LaRosa
    Name:Joseph J. LaRosa
    Title:Executive Vice President, General Counsel and Secretary



    Get the next $REGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $REGN

    DatePrice TargetRatingAnalyst
    8/14/2025$890.00Buy
    Rothschild & Co Redburn
    6/30/2025Buy → Hold
    Argus
    5/30/2025$662.00Outperform → Sector Perform
    RBC Capital Mkts
    5/30/2025$580.00Overweight → Equal Weight
    Wells Fargo
    5/14/2025$700.00Neutral → Buy
    Citigroup
    4/22/2025$695.00Overweight
    Cantor Fitzgerald
    2/5/2025$762.00 → $834.00Market Perform → Outperform
    Leerink Partners
    1/16/2025$1130.00 → $738.00Buy → Neutral
    UBS
    More analyst ratings

    $REGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rothschild & Co Redburn initiated coverage on Regeneron Pharma with a new price target

    Rothschild & Co Redburn initiated coverage of Regeneron Pharma with a rating of Buy and set a new price target of $890.00

    8/14/25 8:22:44 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Pharma downgraded by Argus

    Argus downgraded Regeneron Pharma from Buy to Hold

    6/30/25 8:42:52 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Pharma downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Regeneron Pharma from Outperform to Sector Perform and set a new price target of $662.00

    5/30/25 12:22:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer

    Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone In a five-year analysis, consistent efficacy was observed across histologies with especially notable benefit in the squamous patient population where median overall survival was 22.3 months TARRYTOWN, N.Y., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial, which evaluated Libtayo® (cemiplimab) plus platinum-based chemotherapy versus chemotherapy alone as

    9/9/25 7:00:18 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

    In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo Data from these trials will support further Phase 3 development TARRYTOWN, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced results evaluating its first-in-class investigational allergen-blocking antibodies in allergen-challenge Phase 3 trials in adults with moderate-to-severe cat or birch allergies. Both trials met their respective primary and key secondary endpoints. Data from the Phase 3 trials will be presented at an upcoming medical conference and will inform confirma

    9/8/25 6:30:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Announces Updated Presentation Time for Upcoming Investor Conference

    TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Monday, September 8, 2025. The presentation will be webcast live and may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcast will be archived on the Company's website for at least 30 days. About Regeneron Regeneron (NASDAQ:REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious

    9/4/25 4:05:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 20, 2022 - FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

    For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis

    5/20/22 3:11:09 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Regeneron Pharmaceuticals Inc.

    SCHEDULE 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    8/6/25 12:11:01 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.

    13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    8/1/25 4:09:05 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Regeneron Pharmaceuticals Inc.

    10-Q - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    8/1/25 6:56:11 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schenkein David P was granted 166 shares, increasing direct ownership by 59% to 448 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    1/6/25 5:42:19 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thompson Craig B. was granted 166 shares, increasing direct ownership by 37% to 620 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    1/6/25 4:13:03 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Coles N Anthony was granted 166 shares, increasing direct ownership by 12% to 1,559 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    1/6/25 4:12:14 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Leadership Updates

    Live Leadership Updates

    View All

    Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

    TARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the launch of a pioneering matching program for donations to Good Days, an independent national non-profit charitable organization, to support Good Days' Retinal Vascular and Neovascular Disease Fund. Through this initiative, Regeneron has committed to matching donations up to a total of $200 million at a one-to-one rate for the remainder of the 2025 calendar year, enabling more patients to affordably access essential medicines that help protect their vision. "We are proud to support Good Days with this unprecedented philanthropic effort," said Leonard Schleifer, M.D., Ph.D.,

    6/24/25 7:30:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

    TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities. 2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research & development (R&D) unit to advance cell therapies and combination approaches in oncology and immunology. "Regeneron and 2seventy share a relentless commitment to push the boundaries of scie

    1/30/24 7:00:41 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

    NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

    10/18/23 9:00:00 AM ET
    $AZN
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Financials

    Live finance-specific insights

    View All

    Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

    TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailin

    6/26/25 4:05:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

    TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on Tuesday, April 29, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detai

    3/25/25 4:05:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025

    TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmati

    1/7/25 4:05:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/13/24 5:12:22 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/9/24 6:19:03 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/9/24 9:49:31 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care